The FDA-approved Optilume BPH Catheter System revolutionizes the treatment paradigm by providing immediate and durable symptom relief for men experiencing BPH induced lower urinary tract symptoms, including frequent trips to the bathroom, day and night; weak, slow or intermittent flow; urgent need to pee; and inability to fully empty bladder.
How Does Optilume Catheters Work?
Optilume BPH is a drug-coated balloon that is inserted into the urethra via a telescopic camera, to the prostate. Once in the prostate, the balloon expands creating an opening, and releases the safe and proven drug paclitaxel, into the open prostate. When the drug coating is fully released, the balloon is deflated and removed. The drug prevents re-fusion of the lobes during healing, keeping the prostate open, restoring the flow of urine and relieving bothersome BPH symptoms.
Highlights of the Optilume BPH Catheter System include:
- Clinical studies show Optilume BPH is safe and effective (1,2)
- Immediate and durable symptom relief (1,2)
- Minimal catheter time post-procedure (1,2)
- No impact on sexual function (1,2)
- Quick recovery 1,2)
- Highest clinically reported flow rates of any minimal invasive therapy (2)
- In-office/outpatient procedure
- No cutting, heating, burning, lasering, steaming, or implantation
- Kaplan, Steven; Pichardo, Merycarla; Rijo, Edwin; Lay, Ramon Rodriguez; Espino, Gustavo; Estrella, Rafael MP76-02 AT 4 YEARS, OPTILUME BPH HAS THE HIGHEST SUSTAINED IMPROVEMENT IN PEAK FLOW (QMAX) OF ANY MINIMALLY INVASIVE BPH THERAPY, Journal of Urology: April 2023 – Volume 209 – Issue Supplement 4, doi: 10.1097/JU.0000000000003350.02
- Kaplan, Steven A.*; Moss, Jared; Freedman, Sheldon; Coutinho, Karl; Wu, Ning; Efros, Mitchell; Elterman, Dean; D’Anna, Richard; Padron, Osvaldo; Robertson, Kaiser J.; Lawindy, Samuel; Mistry, Sandeep; Shore, Neal; Spier, Jeffrey; Kaminetsky, Jed; Mazzarella, Brian; Cahn, David; Jalkut, Mark; Te, Alexis The PINNACLE Study: A Double-blind, Randomized, Sham-controlled Study Evaluating the Optilume BPH Catheter System for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia, Journal of Urology: September 2023 – Volume 210 – Issue 3, doi: 10.1097/JU.0000000000003568
For even more information, download our free Optilume Catheter brochure.
The Optilume BPH Catheter System is indicated for the treatment of obstructive urinary symptoms associated with Benign Prostatic Hyperplasia (BPH) in men ≥ 50 years of age. The Optilume BPH Catheter System is contraindicated for use in: Patients with known hypersensitivity to paclitaxel or structurally related compounds, patients with an active urinary tract infection, patients with an artificial urinary sphincter, or patients with a penile prosthesis. The Optilume BPH DCB contains paclitaxel, a known genotoxic aneugen capable of causing chromosomal abnormalities in sperm. Paclitaxel is present in semen for an extended duration after treatment with Optilume BPH. The risks associated with these paclitaxel concentrations in semen are unknown. The effect of treatment with the Optilume BPH DCB on sperm and spermatogenesis is also unknown. Men should abstain from sex or use barrier contraception (wear a condom) for 30 days post treatment to avoid exposure of sexual partner to paclitaxel. Paclitaxel may still be present at low levels after 30 days. Potential adverse effects after treatment with the Optilume BPH Catheter System are similar to standard cystoscopic procedures and mechanical dilation and include, but are not limited to fever, bleeding, pain, urinary tract infection, false route of the urethra, dysuria, difficult urination, frequency/urgency/irritative urinary symptoms, urinary retention and related symptoms, blood in urine (hematuria), urinary incontinence, urethrorrhagia, blood in semen (hematospermia), ejaculatory dysfunction, bladder perforation, urethral and/or bladder neck strictures, injury or perforation to the urethra, sphincter or prostatic capsule, and inflammation of genitourinary system (prostatitis, orchitis, balanitis)
*Trans-women, with or without gender reassignment, may have a prostate. If BPH is diagnosed in a trans-woman, this is managed in the same way as for cisgender men.
Make an appointment today and start enjoying life again.
At Associated Urological Specialists, our experienced BPH urologists and practitioners assess our patients and discuss treatment options with them. Their goal is to find the most effective plan that works best for each individual.
Our goal is to not have you always looking for where the nearest restroom is, wondering whether you can drive somewhere without having to stop, making it through an entire movie, or just being out with family or friends without having to suddenly leave.
Call us today or use the button below to schedule an appointment with any of our board-certified urologists.
Optilume BPH Catheter Appointments at AUS are in Chicago, Southside Chicago and Northwest Indiana.
Benign Prostatic Hyperplasia (BPH) testing and diagnosis can be performed quickly at any of our AUS offices. They are conveniently located in Chicago, Chicago Ridge, Evergreen Park, Homewood, Orland Park and New Lenox, Illinois
Benign Prostatic Hyperplasia (BPH) treatments are done best with AUS.
Patients have learned the most advanced urology procedures, like BPH treatments, are done at AUS. See us if you live in Alsip, Bedford Park, Blue Island, Bridgeview, Burbank, Calumet Park, Chicago Heights, Country Club Hills, Crestwood, Englewood, Glenwood, Harvey, Hickory Hills, Homer Glen, Matteson, Midlothian, Mokena, Oak Lawn, Oak Forest, Olympia Fields, Orland Hills, Park Forest, Roseland, South side, South Holland and Tinley Park. Patients treated successfully at AUS come from Bolingbrook, Brighten Park, Burnham, Burr Ridge, Calumet City, Countryside, Crystal Lawns, Crest Hill, Darien, Dolton, Fairmont, Frankfort, Gage Park, Gillets, Hammond, Hinsdale, Hyde Park, Ingalls Park, Lansing, Lynwood, La Grange, Lemont, Lockport, Munster, Palisades, Richton Park, Riverdale, Romeoville, Sauk Village, South Shore, South Chicago, Westmont, Whiting, Willowbrook and Woodridge.